Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Pharmacol Ther. Jun 6, 2012; 3(3): 34-35
Published online Jun 6, 2012. doi: 10.4292/wjgpt.v3.i3.34
Published online Jun 6, 2012. doi: 10.4292/wjgpt.v3.i3.34
Prolonged fever after Infliximab infusion
Jennifer Katz, Michael Frank, New York University Medical Center, New York, NY 10016, United States
Jennifer Katz, Michael Frank, Lenox Hill Hospital, New York, NY 10075, United States
Author contributions: Katz J and Frank M contributed equally to this manuscript.
Correspondence to: Michael Frank, MD, Lenox Hill Hospital, Lenox Hill, 100 East 77th Street, New York, NY 10075, United States. mikefrankmd@gmail.com
Telephone: +1-212-5937170 Fax: +1-212-8329279
Received: November 3, 2011
Revised: January 31, 2012
Accepted: February 8, 2012
Published online: June 6, 2012
Revised: January 31, 2012
Accepted: February 8, 2012
Published online: June 6, 2012
Abstract
Pharmacologic management for ulcerative colitis (UC) has recently been expanded to include anti- tumor necrosis factor (TNF) therapy for severe disease. Infliximab, a chimeric monoclonal antibody directed again TNF α was first tested in patients with Crohn’s disease. In addition to serious infections, malignancy, drug induced lupus and other autoimmune diseases, serum sickness-like reactions, neurological disease, and infusion reactions further complicate the use of Infliximab. We report a case of prolonged fever after Infliximab infusion to treat steroid refractory UC.
Keywords: Infliximab, Fever, Ulcerative colitis, Crohn’s disease